Context Therapeutics Inc.
CNTXHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeContext Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. At a $22.0M market cap, Context Therapeutics Inc. ranks as a micro-cap company within healthcare. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
Market Cap
$22.0M
Beta
1.72
P/E (TTM)
—
P/E (Fwd)
-0.55
EPS (TTM)
$-0.48
EPS (Fwd)
$-0.44
ROE
-76.1%
ROA
-45.7%
Cash
$43.0M
Total Debt
$244,992
Free CF
-$31.5M
52W Change
-80.6%
Annual Financials
Cash vs Debt
Where CNTX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, CNTX finished 81.25% below its 150-day moving average ($1.28) and 84.21% below its 200-day moving average ($1.52). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CNTX overbought or oversold?
At the October 20, 2026 close, CNTX's RSI(14) was 27.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $43.0M in cash and $245K in debt, CNTX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$31.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -76.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
A beta of 1.72 means CNTX is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. With cash comfortably exceeding debt, CNTX has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing CNTX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.